Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 70
- 试验地点
- 24
- 主要终点
- Rate of composite of major cardiac events
研究概览
简要总结
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System.
The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a dual chamber pacemaker in order to reduce their blood pressure.
The primary objectives of this study are to provide evidence of safety and clinical efficacy of the anti-hypertensive effects of the Moderato System. This will be accomplished by evaluating changes in blood pressure in an active treatment vs. a control patient population for a period of 6 months.
The device will be considered to have a clinical effectiveness with regard to its anti-hypertension functions if there is a statistically significant and clinically meaningful reduction in mean 24-hour ambulatory systolic blood pressure in the treatment group compared to the control group.
详细描述
Protocol CS-03 Ver 1.1 (NCT02837445) was amended at the advice of the Scientific Advisory to protocol CS-03 Version 3.0 with more stringent hypertension inclusion criteria and different observation intervals for efficacy and safety.
In CS-03 Version 3.0 the time of the primary efficacy endpoint was reduced from 6 months to 3 months post randomization which was deemed a suitable interval for the chronic effect, whereas for the safety endpoint, the period was lengthened from 6 month to 12 months post randomization to better monitor potential risks of the treatment on cardiac function (Blinding period was increased from 6 to 12 months). Protocols were thus split in order to allow better clarification to the difference in the time to the primary endpoints for efficacy and safety between the two CIP versions and simplify data analysis.
Protocol Ver 3.0 prescribes data analysis of all patients randomized under version 1.1 to be performed once they complete the 6 months follow-up as set in protocol version 1.1 (NCT0283744). It is expected that ~40 patients will be randomized according to protocol version 1.1 prior to the enrollment of patients according to protocol version 3.0. The results will be considered as interim analysis.
The recruitment for the protocol version 1.1 is now completed. Total of 47 patients were randomized according to protocol version 1.1 and all patients completed the follow-up period for the primary endpoint.
Patients are currently being followed up for the study "extension period".
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject requires an implant or replacement a of dual chamber pacemaker
- •Stable (at least one month) hypertension treatment with at least 1 anti-hypertensive drug, which is anticipated to be maintained for 7 months.
- •Average day time (7AM-10PM) ambulatory systolic blood pressure ≥ 130 mmHg and office blood pressure ≥140 mmHg.
- •Subject lives in the proximity of the study center, which permits compliance with study visits for at least 7 months.
排除标准
- •Known secondary cause of HTN.
- •Average ambulatory or office systolic BP > 195 mmHg.
- •Permanent atrial fibrillation.
- •History of significant paroxysmal atrial fibrillation/flutter burden (defined as >25% of beats).
- •Cardiac ejection fraction <50%.
- •Symptoms of heart failure, NYHA Class II or greater.
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy or inter-ventricular septal thickness ≥ 15 mm.
- •Subject is on dialysis.
- •Subject has an estimated Glomerular Filtration Rate < 30 ml/min/1.73 m²
- •Prior neurological events (stroke or TIA) within the past year or events at a prior time that has resulted in residual neurologic deficit.
- •Carotid artery disease.
- •Known autonomic dysfunction.
- •History of clinically significant untreated ventricular tachyarrhythmia or has experienced sudden death.
- •Previous active device-based treatment for HTN.
- •Existing implant, other than a pacemaker that needs replacing.
- •Subject is or has the possibility of becoming pregnant and is unwilling of contraception during the study.
- •Subject is unwilling or cannot provide Informed Consent
研究组 & 干预措施
Control
Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
干预措施: PHC OFF (Device)
Treatment
Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
干预措施: PHC ON (Device)
结局指标
主要结局
Rate of composite of major cardiac events
时间窗: 6 months post Randomization
including heart failure, clinically significant arrhythmias eg, persistent or increased atrial fibrillation, serious ventricular arrhythmias, myocardial infarction, stroke, heart failure, renal failure and/or related safety events that result in death
Change in average 24 hour systolic ambulatory blood pressure
时间窗: Week 3 pre Randomization and 6 months post Randomization
次要结局
未报告次要终点